<DOC>
	<DOCNO>NCT01066962</DOCNO>
	<brief_summary>The triple therapy darunavir/r + tenofovir/emtricitabine likely become relevant first-line treatment option year come . The dual combination boost darunavir + raltegravir innovative treatment option combine two potent new antiretroviral drug , one belong new drug class ( integrase inhibitor ) . The expected efficacy profile combination promising . Moreover , combination might better tolerance profile advantage spar NRTI class . In context tenofovir/emtricitabine currently reference backbone first-line antiretroviral regimen , hypothesise , combination darunavir/r , raltegravir may alternative option efficacy non-inferior tenofovir/emtricitabine .</brief_summary>
	<brief_title>Study Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir HIV-infected Antiretroviral naïve Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Patient confirm HIV infection Age ≥ 18 year Written inform consent Male patient nonpregnant , nonlactating female No previous treatment antiretroviral drug HIV1 RNA &gt; 1000 copies/ml Indication start antiretroviral treatment long subject also CD4 cell count ≤ 500/mm3 either screen sample take within 3 month screen No major IASUSA mutation genotypic test screen visit historical genotype , available Noninclusion Criteria : Woman without effective contraception method ( recommended contraception trial mechanical + second method oral contraceptive ) Pregnant breastfeed woman Woman expect conceive study HIV2 coinfection Creatinine clearance &lt; 60 ml/mn ( Cockcroft &amp; Gault equation ) , alkaline phosphatase , ASAT , ALAT ≥ 5 ULN Patient significant impairment hepatic function , define serum albumin &lt; 2.8 g/dl INR &gt; 1.7 presence ascites , absence another explanation abnormal find CD4 &gt; 500/mm3 screening , except case symptomatic HIV disease ( defined condition qualify CDC category B C ) CD4 ≤ 500/mm3 sample take within 3 month screen . Any major IASUSA mutation confer resistance one reverse transcriptase protease inhibitor genotypic test screen Mycobacteriosis treatment Malignancy require chemotherapy radiotherapy Positive HBs Ag HCV infection specific treatment ongoing plan first year trial treatment Known hypersensitivity one trial drug excipients Contraindicated concomitant treatment Anticipated noncompliance protocol Participation another clinical trial ongoing exclusion period screen Subject legal guardianship incapacitation Subject , opinion investigator , unable complete study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HIV-infected antiretroviral naïve subject</keyword>
</DOC>